Circio: First patient in multiple myeloma trial dosed with TG01 at Oslo University Hospital
· TG01 monotherapy will be evaluated in 20 patients with RAS-mutated multiple myeloma. · The trial is sponsored by Oslo University Hospital and led by Dr. Fredrik Schjesvold, an international leader in the field and founder of the Oslo Myeloma Center, the largest Myeloma center in the NordicsOslo, Norway, 22 June 2023 - Circio Holding ASA (OSE: CRNA), today announces that the first multiple myeloma (MM) patient has been dosed with mutant RAS cancer vaccine TG01 at Oslo University Hospital (OUS). The study is led by multiple myeloma expert Dr. Fredrik Schjesvold in a clinical